DURGA-4
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Near Add Your Location
Sorting 19 by
Memorial Sloan Kettering Cancer Center
New York, NY
- Not yet accepting
Mayo Clinic (Arizona)
Phoenix, AZ
- Not yet accepting
- Not yet accepting
- Not yet accepting
Swedish - First Hill Campus
Seattle, WA
- Not yet accepting
Novant Health Forsyth Cancer Institute - Bethesda Court
Winston-Salem, NC
- Not yet accepting
University of Kansas Cancer Center
Kansas City, KS
- Not yet accepting
- Accepting patients
Massachusetts General Hospital
Boston, MA
- Not yet accepting
- Not yet accepting
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.